Altoida is defining a new category in neurological care with a first-of-its-kind, AI- and AR-powered digital biomarker platform for clinical-grade cognitive and functional assessment. Its 10-minute, self-administered Digital NeuroMarker Platform captures millions of multimodal data points across motor, speech, and cognitive domains, enabling earlier and more objective detection of Mild Cognitive Impairment (MCI) and related neurodegenerative diseases.

Built on over 20 years of research and more than 42,000 tests across 20,000 participants in academic and global pharma trials, Altoida’s platform has been independently researched and peer-reviewed in Nature Digital Medicine. With an estimated 200 million undiagnosed MCI patients worldwide, established billing codes, and disease-modifying therapies on the market, Altoida is uniquely positioned to address a $7B+ near-term opportunity and support earlier, more impactful clinical intervention.

For more information, visit www.altoida.com.